For instance, there is higher ATP-binding cassette transporter expression in CD34+/CD38− AML cells compared with CD34+/CD38+ AML cells (3), and a subset of CD34+/CD38− cells is able to resist venetoclax by altering what substrates are used to fuel the tricarboxylic acid cycle and oxidative phosphorylation (4). This evidence concerns the gene CD34 and acute myeloid leukemia.